Compare XWEL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XWEL | SKYE |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 9.0M |
| IPO Year | 2010 | 2013 |
| Metric | XWEL | SKYE |
|---|---|---|
| Price | $0.82 | $1.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $68.00 |
| AVG Volume (30 Days) | 17.0K | ★ 78.1K |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,210,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.26 | $0.26 |
| 52 Week High | $2.20 | $4.99 |
| Indicator | XWEL | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 33.39 | 48.66 |
| Support Level | $0.33 | $1.57 |
| Resistance Level | $0.95 | $2.28 |
| Average True Range (ATR) | 0.03 | 0.20 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 3.06 | 10.61 |
XWELL Inc is an international wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment, which generates maximum revenue, operates spa service locations in airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program. The Naples Wax Center segment operates six locations offering face and body waxing, skincare services, and cosmetic products. The Company generates maximum revenue from the United States.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.